Biomet Inc. Nov 07

  • ID: 2197387
  • November 2007
  • Standard & Poors
1 of 3

One of the leading providers of orthopedic products; Long-standing customer relationships; and Operates in an industry characterized by stable market share. High debt leverage; Very high interest expense; and Concentration in reconstructive products. The ratings on Warsaw, Ind.-based Biomet Inc. reflect a satisfactory business risk profile, largely offset by high debt leverage: Debt to EBITDA is about 8x as a result of a sponsor buyout. Given Standard & Poor's Ratings Services' expectation of only moderate cash flow relative to debt, the company's ability to deleverage will, to a great extent, be a function of its ability to increase EBITDA over the next several years. Biomet designs, manufactures, and markets products used primarily by musculoskeletal medical specialists in both surgical and...

Companies mentioned in this report are:
- Biomet Inc.

Action: Review

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

- Biomet Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.